Expression Therapeutics LLC, of Tucker, Ga., entered a deal with biomedical contract research and manufacturing organization ABL Inc., which will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy. Financial terms were not disclosed.